You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Cobas m 511 combines a cell counter, slide maker and stainer, and a digital morphology analyzer into one integrated solution.
Among companies whose tests were greenlighted by the FDA last month, Quidel received clearances for a test to detect and differentiate influenza types A and B, and for a separate test for Lyme disease.
For full-year 2017, the company reported $152.9 million in revenues, up 31 percent over 2016.
Streck claims that the blood collection tubes in the Roche Ariosa Harmony kit that Cenata uses infringe its patent.
A broad team of researchers has developed a microarray that looks for 171,000 different peptide fragments to differentiate among tick-borne diseases.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
Guardant Health said that its Guardant360 liquid biopsy assay has received expedited access pathway designation from the US Food and Drug Administration.
The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.
Danish IVD firm BioPorto will distribute a version of its NGAL Test for use on the Cobas c 501/
Alere received FDA 510(k) clearances for four tests, including those for influenza A and B, strep A, and RNA-based respiratory syncytial virus.